Alterations in brain network connectivity and subjective experience induced by psychedelics: a scoping review
Zijia Yu, Lisa Burback, Olga Winkler, Lujie Xu, Liz Dennett, Eric Vermetten, Fei Wang, Bo Cao, Yanbo Zhang, Andrew J. Greenshaw, Xin-Min Li, M. D. Milne, Ian R. Winship, Allen W. Chan
Frontiers in Psychiatry May 14, 2024 DOI: 10.3389/fpsyt.2024.1386321 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Scoping review Peer reviewed |
|---|---|
| Population | Healthy individuals |
| Interventions | Ayahuasca Psilocybin LSD MDMA |
| Keywords | Functional connectivity |
| Citations | 38 |
| Key findings | Psychedelics consistently decrease default mode network connectivity and increase sensory and thalamocortical connectivity, correlating with subjective experiences of altered consciousness, mood elevation, and mystical experiences. |
Abstract
Intense interest surrounds current research on psychedelics, particularly regarding their potential in treating mental health disorders. Various studies suggest a link between the subjective effects produced by psychedelics and their therapeutic efficacy. Neuroimaging evidence indicates an association of changes in brain functional connectivity with the subjective effects of psychedelics. We conducted a review focusing on psychedelics and brain functional connectivity. The review focused on four psychedelic drugs: ayahuasca, psilocybin and LSD, and the entactogen MDMA. We conducted searches in databases of MEDLINE, Embase, APA PsycInfo and Scopus from inception to Jun 2023 by keywords related to functional connectivity and psychedelics. Using the PRISMA framework, we selected 24 articles from an initial pool of 492 for analysis. This scoping review and analysis investigated the effects of psychedelics on subjective experiences and brain functional connectivity in healthy individuals. The studies quantified subjective effects through psychometric scales, revealing significant experiences of altered consciousness, mood elevation, and mystical experiences induced by psychedelics. Neuroimaging results indicated alterations in the functional connectivity of psychedelics, with consistent findings across substances of decreased connectivity within the default mode network and increased sensory and thalamocortical connectivity. Correlations between these neurophysiological changes and subjective experiences were noted, suggesting a brain network basis of the psychedelics’ neuropsychological impact. While the result of the review provides a potential neural mechanism of the subjective effects of psychedelics, direct clinical evidence is needed to advance their clinical outcomes. Our research serves as a foundation for further exploration of the therapeutic potential of psychedelics.
Citations in the library
Cited by 34
- Uncovering Psychedelics: From Neural Circuits to Therapeutic Applications Pharmaceuticals January 19, 2025
- Psilocybin as Transformative Fast‐Acting Antidepressant: Pharmacological Properties and Molecular Mechanisms Fundamental and Clinical Pharmacology July 16, 2025
- Artificial intelligence and psychedelic medicine Annals of the New York Academy of Sciences September 23, 2024
- Psychedelics for the treatment of end-of-life distress in patients with a life-threatening disease. International review of neurobiology 2025
- Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology British Journal of Pharmacology September 2, 2025
and 29 more in the library
Cites 61
- The benefits of being present: Mindfulness and its role in psychological well-being. Journal of Personality and Social Psychology 2003
- The Brain's Default Mode Network Annual Review of Neuroscience May 4, 2015
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
and 56 more in the library